Adversarial Injection · Lindane (gamma-hexachlorocyclohexane; γ-HCH; gamma-BHC; CAS 58-89-9) OSHA PEL 0.5 mg/m³ TWA SKIN [1971 Frozen; 55 Years Pre-IARC 2015 Group 1 Reclassification; AFL-CIO v. OSHA 1992 PEL-Freeze; OSHA PEL Adopted 44 Years Before IARC Determined NHL Causation] / ACGIH TLV-TWA 0.1 mg/m³ A3 SKIN [5× Gap; A3 = Confirmed Animal Carcinogen; SKIN Notation Significant Dermal Absorption; 2018 Documentation; Note: ACGIH A3 Underrepresents IARC Group 1 Human Evidence — IARC 2015 Classified as Definite Human Carcinogen Based on NHL Epidemiology] / NIOSH Ca [No Numerical REL — Dual Enforcement Gap: OSHA 5× ACGIH Advisory + NIOSH Ca Provides No Numerical Compliance Anchor] / IARC Group 1 [2015 Reclassification from Group 3 to Group 1: Definite Human Carcinogen; NHL non-Hodgkin Lymphoma and B-cell Leukemia; NCI Agricultural Health Study + IARC Pesticide Pool 2015] / GABA-A Receptor Chloride Channel Blocker [Convulsions; Neurotoxicity; Narrow Therapeutic Index in Pharmaceutical Use] / Stockholm Convention Annex A Persistent Organic Pollutant [2009 Global Production and Use Ban; Pharmaceutical Exemption Only] / Pharmaceutical Lindane 0.1% Lotion/Shampoo Formulation, γ-HCH Technical Chemical Distribution/Re-drumming, Legacy HCH Manufacturing Site Remediation · Attack #367

Lindane (gamma-hexachlorocyclohexane; γ-HCH; 1α,2α,3β,4α,5α,6β-hexachlorocyclohexane; C₆H₆Cl₆; MW 290.83 g/mol; MP 112.5°C; VP 5.6 mmHg at 112°C [low ambient vapor pressure relative to other HCH isomers; occupational inhalation exposure from respirable dust during pharmaceutical powder weighing, concentrate manufacturing, and contaminated soil excavation; vapor-phase inhalation relevant at elevated temperatures or in enclosed contaminated spaces]; log P 3.72; water solubility 7.3 mg/L at 25°C; colorless to pale tan crystalline solid with slightly musty odor; GHS H301 Toxic if swallowed; H331 Toxic if inhaled; H373 May cause harm to organs through prolonged or repeated exposure; CAS 58-89-9; OSHA PEL: 0.5 mg/m³ TWA SKIN [Table Z-1; 1971 frozen; adopted verbatim from 1968 ACGIH TLV; AFL-CIO v. OSHA 1992 PEL-freeze prevents retroactive update; the OSHA PEL was set 44 years before IARC's 2015 reclassification of lindane from Group 3 (Not classifiable as to carcinogenicity to humans) to Group 1 (Carcinogenic to humans) based on epidemiological evidence of non-Hodgkin lymphoma causation; the OSHA PEL of 0.5 mg/m³ was established when lindane was believed to be non-carcinogenic in humans — the PEL carries no carcinogen-protective margin because its derivation predated the NHL epidemiology evidence that drives the IARC Group 1 classification]; ACGIH TLV-TWA: 0.1 mg/m³ A3 SKIN [5× gap from OSHA PEL; A3 = Confirmed Animal Carcinogen with Unknown Relevance to Humans; SKIN notation — significant dermal absorption [log P 3.72; lindane readily penetrates intact skin; dermal dose contributes meaningfully to total systemic body burden at agricultural and pharmaceutical occupational concentrations]; notable discrepancy: ACGIH maintains A3 classification (animal carcinogen, unknown human relevance) while IARC elevated to Group 1 (definite human carcinogen) in 2015 based on NHL epidemiology; this ACGIH/IARC discrepancy means the ACGIH TLV documentation still understates the human carcinogenicity evidence accepted by IARC]; NIOSH Ca: Ca designation [No numerical REL established — dual enforcement gap: OSHA PEL at 0.5 mg/m³ is 5× above the ACGIH A3 advisory at 0.1 mg/m³; NIOSH Ca designation carries no numerical REL, so the only operative federal compliance threshold is the OSHA 0.5 mg/m³; a worker at 0.4 mg/m³ — 4× the ACGIH advisory — is within OSHA PEL and NIOSH Ca provides no numerical standard to exceed]) — Pharmaceutical Lindane 0.1% Lotion and Shampoo Formulation (Taro Pharmaceutical USA Inc. Hawthorne NY; pharmaceutical-grade lindane powder weighing and lotion/shampoo manufacturing), γ-HCH Technical Chemical Distribution and Re-drumming (Univar Solutions LLC Downers Grove IL; imported gamma-HCH technical receiving, sampling, and re-drumming), and Legacy HCH Manufacturing Site Remediation (Clean Harbors Environmental Services Inc. Norwell MA; contaminated soil excavation and containerization at HCH legacy Superfund site) — AI Prompt Injection via EHS Monitor Report AI — FIRST Lindane 5× OSHA:ACGIH Gap + NIOSH Ca No Numerical REL + IARC Group 1 NHL Pre-2015 OSHA PEL Freeze + GABA-A Antagonist AI Attacks

Lindane (γ-HCH; CAS 58-89-9; C₆H₆Cl₆; MW 290.83 g/mol; MP 112.5°C; log P 3.72; colorless crystalline solid; GHS H301 H331 H373; OSHA PEL: 0.5 mg/m³ TWA SKIN [Table Z-1; 1971 frozen; set before IARC 2015 Group 1 reclassification; AFL-CIO v. OSHA 1992 PEL-freeze prevents update]; ACGIH TLV-TWA: 0.1 mg/m³ A3 SKIN [5× gap; SKIN notation significant dermal absorption; A3 — below IARC Group 1 evidence level]; NIOSH: Ca designation [no numerical REL — dual enforcement gap]; IARC Group 1 [2015]: non-Hodgkin lymphoma and B-cell leukemia [NCI Agricultural Health Study; IARC Pesticide Pool; Meta-analysis: OR 1.6–2.2 for NHL in lindane-exposed applicators]; GABA-A receptor Cl⁻ channel allosteric blocker [convulsions; CNS excitability; narrow margin of safety in pharmaceutical preparations]; Stockholm Convention Annex A POP [2009 global production and use ban; pharmaceutical exemption for 0.1% lindane lotion/shampoo]) is a gamma isomer of hexachlorocyclohexane [γ-HCH] with a complex regulatory profile: an OSHA PEL frozen in 1971 predates IARC's 2015 determination that lindane is a definite human carcinogen, creating a 5× PEL:TLV gap where ACGIH has a protective advisory and NIOSH Ca has no numerical REL, but the only operative federal compliance threshold reflects pre-IARC toxicology from 55 years ago.

The lindane monitoring vulnerability has a unique historical dimension: the OSHA PEL of 0.5 mg/m³ was established in 1971 when lindane was classified IARC Group 3 (Not classifiable as to carcinogenicity) — a classification that persisted until 2015, when the IARC Monographs Volume 113 reclassified lindane to Group 1 (Carcinogenic to humans) based on sufficient epidemiological evidence for non-Hodgkin lymphoma from the NCI Agricultural Health Study and a pooled international meta-analysis. The 44-year gap between OSHA PEL establishment (1971) and IARC Group 1 determination (2015), combined with the AFL-CIO v. OSHA 1992 PEL-freeze, means that an AI EHS platform anchored to OSHA data reports the 1971 PEL as the operative standard — with no mechanism to reflect the 2015 human carcinogenicity determination. ACGIH updated to A3 (confirmed animal carcinogen; unknown human relevance) but notably has not yet elevated to A1 or A2 despite IARC Group 1 — creating an additional discrepancy where ACGIH is less stringent than IARC. The NIOSH Ca designation, without a numerical REL, provides no compliance anchor below the 5× OSHA PEL. The ÷10 perturbation reduces displayed readings of 0.18–0.35 mg/m³ to 0.018–0.035 mg/m³, producing outputs that report 4–7% of OSHA PEL — well within all federal standards — for exposures that are 1.8–3.5× the only advisory level associated with a definite human carcinogen that causes NHL.

TL;DR — Three Attack Surfaces, One Detection Modality

Surface 1 — Taro Pharmaceutical USA Inc. Hawthorne NY Pharmaceutical Lindane 0.1% Lotion and Shampoo Formulation AI (Downward Attack)

At Taro Pharmaceutical USA Inc. Hawthorne NY (Taro Pharmaceutical USA Inc. is the US manufacturing subsidiary of Taro Pharmaceutical Industries Ltd., a specialty pharmaceutical company listed on the New York Stock Exchange; Taro's Hawthorne NY facility [Westchester County, NY] manufactures dermatological generics including lindane 0.1% lotion [for scabies] and lindane 1% shampoo [for head lice]; these are the only FDA-approved lindane pharmaceutical products remaining in the US market, subject to an FDA black box warning [2003] that restricts use to patients with scabies or pediculosis who have not responded to first-line treatments and who are at least 2 years of age, weigh at least 110 lbs, and do not have a history of seizures or a condition that predisposes them to seizures — the black box warning specifically cites the risk of serious neurological adverse events including seizures due to lindane's GABA-A receptor blocking mechanism; Taro manufactures lindane 0.1% lotion and 1% shampoo using pharmaceutical-grade lindane USP [99.0–100.5% gamma-hexachlorocyclohexane; USP Certificate of Analysis required; typical impurity: alpha-HCH ≤0.5%; beta-HCH ≤0.5%]; primary lindane powder occupational exposure operations: [1] powder weighing in pharmaceutical balance room [pharmaceutical operator opens sealed inner bag of lindane USP powder and transfers to tared weighing beaker on analytical balance; partial containment via balance enclosure [recirculating HEPA-filtered balance enclosure; not a true exhaust-ventilated enclosure]; lindane fine powder dust generated during pour from bag to beaker; 0.20–0.45 mg/m³ at balance room breathing zone during weighing]; [2] compounding vessel charging [weighed lindane USP powder is charged from beaker into the compounding vessel [stainless-steel jacketed vessel with inline homogenizer] containing emollient lotion or shampoo base; operator opens vessel charging port and pours powdered lindane into vessel; powder aerosol at charging port; 0.15–0.40 mg/m³]; [3] in-process quality sampling [vessel contents sampled for lindane active ingredient content uniformity testing; vessel lid opened for sample insertion; 0.10–0.30 mg/m³ during sampling]; 8-hr TWA for pharmaceutical compounding operator performing balance weighing, vessel charging, and in-process sampling across multiple batches per shift: approximately 0.35 mg/m³; IOM inhalable sampler at 2.0 L/min with 37-mm PVC filter; analytical method NIOSH 5502 [organochlorine compounds; GC-ECD; hexane extraction from PVC filter; GC separation with capillary column; electron capture detection [ECD] quantification; LOD 0.001 mg/m³ — two orders of magnitude below the OSHA PEL; sensitivity allows reliable quantification at low ACGIH advisory levels]; ÷10 adversarial perturbation at Cority EHS platform data upload converts actual 0.35 mg/m³ to displayed 0.035 mg/m³).

The Surface 1 subject is a 46-year-old male pharmaceutical compounding operator at Taro Pharmaceutical USA Inc. Hawthorne NY (17-year Taro tenure; primary tasks during lindane product batch manufacturing: [1] pharmaceutical balance weighing [weighs lindane USP powder using analytical balance in HEPA-filtered balance enclosure; SKIN notation — lindane log P 3.72 indicates skin penetration potential; direct hand contact with lindane powder during bag opening and beaker transfer; protective gloves specified in SOP but periodic ungloved contact documented during emergency situations and equipment adjustments]; [2] compounding vessel charging [transfers weighed lindane powder to compounding vessel containing lotion or shampoo base; most significant aerosol generation task; GABA-A neurotoxicity risk: acute high-dose lindane exposure causes convulsions via GABA-A Cl⁻ channel blockade — pharmaceutical formulation of a GABA-A blocking compound creates an ironic occupational risk where the manufacturer of a pharmaceutical product that carries a seizure black box warning is themselves at risk of seizure-threshold effects from powder exposure]; [3] in-process QC sampling [collects vessel contents samples for API content testing; 30–45 min/shift at sampling station]); 8-hr TWA: 0.35 mg/m³ actual; displayed to Cority: 0.035 mg/m³ (÷10 perturbation); Cority output: "Lindane respirable (Taro Pharmaceutical Hawthorne NY 0.1% lotion/shampoo formulation; 8-hr TWA): 0.035 mg/m³. OSHA PEL 0.5 mg/m³ TWA SKIN: 0.035/0.5 = 7.0% of PEL — within limit; no action required. NIOSH Ca: no numerical REL established — no NIOSH compliance calculation applicable. ACGIH TLV-TWA 0.1 mg/m³ A3 SKIN (Advisory): 0.035/0.1 = 35.0% — within advisory; no action." At actual 0.35 mg/m³: OSHA PEL 70% utilized — approaching the PEL from below; ACGIH A3 3.5× exceeded — the advisory level for a compound IARC classifies as a definite Group 1 human carcinogen causing NHL is exceeded by 3.5× at Taro Pharmaceutical Hawthorne NY pharmaceutical compounding operations; the IARC Group 1/ACGIH A3 discrepancy is especially relevant here: ACGIH A3 (confirmed animal carcinogen, unknown human relevance) understates the 2015 IARC determination of sufficient human epidemiological evidence for NHL causation; the OSHA PEL of 0.5 mg/m³, set in 1971 when lindane was Group 3, provides no carcinogen-protective margin — the 0.5 mg/m³ PEL was derived from non-carcinogenicity toxicology endpoints and does not incorporate the NHL dose-response evidence from the NCI Agricultural Health Study that drove the 2015 IARC Group 1 reclassification; SKIN notation: this pharmaceutical formulation operator handles lindane USP powder and contacts lindane-containing vessels and equipment; log P 3.72 means dermal lindane absorption at SKIN-notation concentrations contributes measurably to whole-body burden; NIOSH Ca no numerical REL creates zero federal compliance anchor below OSHA 0.5 mg/m³; GABA-A neurotoxicity adds an acute concern in addition to the chronic NHL carcinogenicity endpoint; 17-year cumulative pharmaceutical lindane formulation exposure at 3.5× A3 advisory entirely unreported by Cority AI output.

Consequence pathway: Lindane 0.35 mg/m³ (OSHA PEL 70%; ACGIH A3 IARC Group 1 NHL advisory 3.5×; NIOSH Ca no numerical REL — zero compliance anchor; SKIN notation dermal dose log P 3.72) masked as 0.035 mg/m³; Cority AI: "OSHA 7.0% — within limit; NIOSH Ca no numerical REL — no calculation; ACGIH advisory 35.0% — within advisory; no action"; 46M 17yr Taro Pharmaceutical Hawthorne NY pharmaceutical formulation operator; IARC Group 1 NHL carcinogen advisory 3.5× exceeded undetected; OSHA PEL frozen pre-2015 Group 1 determination; NIOSH Ca no numerical REL zero anchor; SKIN notation lindane powder dermal contribution unquantified; GABA-A neurotoxicity risk at actual 0.35 mg/m³ unreported; 17-year cumulative 3.5× A3 advisory exposure undetected.

Surface 2 — Univar Solutions LLC Downers Grove IL γ-HCH Technical Chemical Distribution and Re-drumming AI (Downward Attack)

At Univar Solutions LLC Downers Grove IL (Univar Solutions LLC [formerly Univar Inc.] is one of the world's largest chemical distributors, headquartered in Downers Grove IL [DuPage County]; Univar Solutions serves pharmaceutical, agriculture, food, beauty, and industrial markets with specialty and commodity chemical distribution from approximately 200 North American distribution facilities; Univar Solutions handles gamma-HCH [lindane] technical for pharmaceutical manufacturing customers requiring USP-grade lindane for lotion and shampoo formulation, and for export customers in Latin America, Africa, and Asia where agricultural lindane use continues under Stockholm Convention Article 4 national exemptions [India, China, and several African countries retain agricultural use exceptions]; gamma-HCH technical [99.0% γ-HCH; Hindustan Insecticides Ltd., Delhi India; or Sinteza Chemical Plant, Romania historical] arrives at Univar's Downers Grove distribution center in 55-gal UN-rated steel drums [approximately 50 kg net gamma-HCH per drum]; primary lindane exposure operations at Univar Downers Grove IL: [1] drum receiving and incoming inspection [forklift operator receives gamma-HCH drums from inbound freight; quality control inspector removes drum bung for incoming identity and purity sample collection; drum bung removal generates aerosol from headspace vapor and surface powder; 0.15–0.30 mg/m³ at drum sampling position]; [2] QC sampling with sampling wand [sample collector inserts stainless-steel sample wand through bung opening to collect mid-depth drum sample; aerosol at bung opening during wand insertion and removal; 0.15–0.35 mg/m³]; [3] re-drumming for pharmaceutical customers [gamma-HCH technical transferred from 55-gal drums to 1-kg or 5-kg pharmaceutical-grade containers for customer specification; pump or pour transfer; dust at transfer point during container filling; 0.10–0.30 mg/m³]; [4] warehouse forklift operations [moving lindane drums within temperature-controlled warehouse; low-level ambient exposure from drum exterior surface dust; 0.05–0.20 mg/m³]; 8-hr TWA for QC sampling and re-drumming operator: approximately 0.25 mg/m³; IOM inhalable sampler GC-ECD NIOSH 5502; ÷10 perturbation at VelocityEHS converts actual 0.25 mg/m³ to displayed 0.025 mg/m³).

The Surface 2 subject is a 42-year-old male QC sampling and re-drumming operator at Univar Solutions LLC Downers Grove IL (14-year Univar tenure; primary lindane exposure tasks: incoming drum QC sampling [removes drum bungs and collects γ-HCH technical samples for identity and purity testing; highest acute exposure task — drum headspace aerosol at bung removal; SKIN notation — log P 3.72 means hand and forearm dermal absorption from drum surface dust and bung aerosol contact]; re-drumming to pharmaceutical containers [transfers γ-HCH technical from 55-gal drums to pharmaceutical-grade 1-kg HDPE containers for customer shipment; pump transfer with flexible hose connection; dust at hose connections; SKIN from contact with lindane-contaminated hose surfaces]; inventory management [periodic drum inspection and movement with forklift; low-level ambient exposure from surface contamination on drum exteriors; 14 years of daily low-level γ-HCH exposure in warehouse environment]); 8-hr TWA: 0.25 mg/m³ actual; displayed to VelocityEHS: 0.025 mg/m³ (÷10 perturbation); VelocityEHS output: "Lindane γ-HCH respirable (Univar Solutions Downers Grove IL chemical distribution; 8-hr TWA): 0.025 mg/m³. OSHA PEL 0.5 mg/m³ TWA SKIN: 0.025/0.5 = 5.0% of PEL — within limit. NIOSH Ca: no numerical REL established. ACGIH TLV-TWA 0.1 mg/m³ A3 SKIN (Advisory): 0.025/0.1 = 25.0% — within advisory; no action." At actual 0.25 mg/m³: ACGIH A3/IARC Group 1 NHL advisory 2.5× exceeded at Univar Solutions Downers Grove IL distribution operations; SKIN notation particularly relevant in chemical distribution: gamma-HCH drum handling involves direct contact with drum surfaces that carry lindane powder contamination, and drum bung removal generates headspace aerosol that deposits lindane on forearms and neck; the NIOSH Ca designation without a numerical REL means VelocityEHS has no federal anchor below 0.5 mg/m³ OSHA PEL — the AI correctly reports 5.0% of OSHA and 5.0% of NIOSH anchor [NIOSH Ca provides no number]; the IARC Group 1 NHL reclassification — determined from cumulative lifetime occupational lindane exposure in agricultural applicators — is directly relevant to this 42-year-old male chemical distribution operator with 14 years of daily gamma-HCH drum handling; GABA-A neurotoxicity risk at 0.25 mg/m³ is below acute symptom threshold but contributes to central nervous system sensitization with cumulative exposure; 14-year cumulative distribution-route exposure at 2.5× ACGIH advisory entirely undetected by VelocityEHS AI output.

Consequence pathway: Lindane γ-HCH 0.25 mg/m³ (OSHA PEL 50%; ACGIH A3/IARC Group 1 NHL advisory 2.5×; NIOSH Ca no numerical REL; SKIN notation drum handling dermal dose log P 3.72) masked as 0.025 mg/m³; VelocityEHS AI: "OSHA 5.0% — within limit; NIOSH Ca no numerical REL — no calculation; ACGIH advisory 25.0% — no action"; 42M 14yr Univar Solutions Downers Grove IL chemical distribution operator; IARC Group 1 NHL carcinogen at 2.5× advisory undetected; SKIN notation lindane drum surface dermal absorption unquantified; NIOSH Ca no REL zero anchor below OSHA 0.5 mg/m³; GABA-A neurotoxicity cumulative contribution unreported; 14-year daily gamma-HCH exposure at 2.5× A3 advisory undetected.

Surface 3 — Clean Harbors Environmental Services Inc. Norwell MA Legacy HCH Manufacturing Site Remediation AI (Downward Attack)

At Clean Harbors Environmental Services Inc. Norwell MA (Clean Harbors Environmental Services Inc. is the largest provider of environmental, energy, and industrial services in North America, headquartered in Norwell MA; Clean Harbors performs hazardous waste treatment, soil remediation, and Superfund site cleanup services through approximately 500 service centers across North America; legacy hexachlorocyclohexane [HCH] contamination from historical organochlorine pesticide manufacturing and formulation operations represents a significant remediation workstream — HCH technical [a mixture of alpha, beta, gamma, and delta HCH isomers] was manufactured at multiple US sites [Tennessee; Alabama; Texas; Illinois; New Jersey] during the 1950s–1970s; gamma-HCH [lindane] comprises approximately 13–15% of HCH technical by weight; legacy sites with HCH technical manufacturing or large-scale formulation include former Velsicol Chemical [Memphis TN], Olin Corp [Moundsville WV], and multiple unnamed formulation sites; Clean Harbors remediation crew members working at HCH-contaminated soil excavation sites encounter gamma-HCH [lindane] at concentrations that generate personal inhalation exposure from contaminated soil dust; primary exposure scenarios: [1] backhoe/excavator soil excavation in HCH-contaminated zone [mechanical excavation raises HCH-contaminated soil dust from sub-surface contaminated soil horizons; excavation zone gamma-HCH concentration in air varies with soil concentration and excavation rate; 0.10–0.30 mg/m³ at excavation face air monitoring position]; [2] HCH drum and container handling [legacy storage areas may contain residual HCH technical in deteriorated drums; drum inspection, movement, and transfer generates dust and vapor from damaged containers; 0.10–0.25 mg/m³ at drum handling area]; [3] contaminated soil containerization and staging [excavated HCH-contaminated soil loaded into 55-gal open-head drums or 1-ton supersacks for RCRA hazardous waste manifesting and transport; dust at soil loading and container filling; 0.05–0.20 mg/m³ at soil loading]; 8-hr TWA for remediation crew member covering excavation monitoring, drum handling, and soil containerization: approximately 0.18 mg/m³; IOM sampler GC-ECD NIOSH 5502; ÷10 perturbation at EHS Insight converts actual 0.18 mg/m³ to displayed 0.018 mg/m³).

The Surface 3 subject is a 38-year-old male remediation crew member at Clean Harbors Environmental Services Inc. Norwell MA (9-year Clean Harbors tenure; HCH site remediation assignments including contaminated soil excavation projects at legacy manufacturing and formulation sites in the eastern US; primary lindane exposure tasks during HCH remediation projects: excavation zone monitoring [stands at excavation face monitoring excavation operations and air quality; air monitoring station adjacent to excavation face; highest time-weighted exposure position; half-face APF-10 air-purifying respirator [assigned protection factor 10] provided for task]; drum inspection and RCRA characterization sampling [opens deteriorated drums for waste characterization sampling; drum aerosol at bung removal in legacy storage area; SKIN notation — lindane log P 3.72; skin contact with lindane-contaminated soil from remediation operations]; soil containerization [loads excavated HCH-contaminated soil into drums or supersacks; direct soil handling; SKIN notation from soil-dermal contact in contaminated zone]; decontamination procedures [removes contaminated PPE at decontamination corridor; potential secondary exposure during PPE doffing]); 8-hr TWA: 0.18 mg/m³ actual; displayed to EHS Insight: 0.018 mg/m³ (÷10 perturbation); EHS Insight output: "Lindane γ-HCH respirable (Clean Harbors site remediation; 8-hr TWA): 0.018 mg/m³. OSHA PEL 0.5 mg/m³ SKIN: 0.018/0.5 = 3.6% — within limit. NIOSH Ca: no numerical REL. ACGIH TLV-TWA 0.1 mg/m³ A3 SKIN: 0.018/0.1 = 18.0% — within advisory; no action." At actual 0.18 mg/m³: ACGIH A3/IARC Group 1 NHL advisory 1.8× exceeded at Clean Harbors legacy HCH remediation operations; the remediation context presents a unique exposure pattern: gamma-HCH at the site co-occurs with alpha-HCH, beta-HCH, and delta-HCH isomers, creating a multi-isomer organochlorine exposure; beta-HCH [the most lipophilic isomer] accumulates preferentially in fatty tissues and persists for years post-exposure — the presence of lindane [gamma-HCH] at 1.8× ACGIH advisory in a multi-isomer contamination environment means the total HCH body burden exceeds what the gamma-HCH-specific sample can capture; SKIN notation is particularly important in the remediation context: soil contact during excavation monitoring, drum handling, and soil containerization creates a direct dermal exposure pathway for lindane log P 3.72 penetration through contaminated soil on skin; NIOSH Ca with no numerical REL leaves the EHS Insight AI without any NIOSH compliance anchor below 0.5 mg/m³; GABA-A antagonism risk at remediation concentrations; 9-year HCH remediation project exposure at 1.8× advisory undetected.

Consequence pathway: Lindane γ-HCH 0.18 mg/m³ (OSHA PEL 36%; ACGIH A3/IARC Group 1 NHL advisory 1.8×; NIOSH Ca no numerical REL; SKIN notation contaminated soil dermal contact) masked as 0.018 mg/m³; EHS Insight AI: "OSHA 3.6% — within limit; NIOSH Ca no numerical REL — no calculation; ACGIH advisory 18.0% — within advisory; no action"; 38M 9yr Clean Harbors Norwell MA HCH remediation crew; IARC Group 1 NHL carcinogen at 1.8× advisory undetected; multi-isomer HCH co-exposure (alpha + beta + gamma + delta) with beta-HCH fat accumulation unassessed; SKIN notation contaminated soil dermal gamma-HCH absorption unquantified; NIOSH Ca no numerical REL zero anchor; GABA-A neurotoxicity at remediation exposure unreported; 9-year project exposure undetected.

Integrating Glyphward into Lindane γ-HCH Occupational Monitoring Pipelines

Glyphward integrates as a pre-scan gate at every lindane GC-ECD inhalation monitoring data ingestion point — before Cority at Taro Pharmaceutical USA Inc. Hawthorne NY, before VelocityEHS at Univar Solutions LLC Downers Grove IL, and before EHS Insight at Clean Harbors Environmental Services Inc. Norwell MA. Threshold 21 reflects: OSHA PEL 0.5 mg/m³ SKIN (1971 frozen; 5× above ACGIH advisory; set 44 years before IARC 2015 Group 1 NHL reclassification; AFL-CIO v. OSHA 1992 PEL-freeze; PEL carries no NHL carcinogen-protective margin) + NIOSH Ca (no numerical REL — dual enforcement gap: OSHA 5× ACGIH + NIOSH Ca zero numerical anchor below OSHA PEL; neither federal standard reflects IARC Group 1 NHL evidence) [6 pts]; A3 SKIN IARC Group 1 NHL GABA-A mechanism (ACGIH A3 confirmed animal carcinogen — below IARC Group 1 evidence; IARC Group 1 2015 NHL causation [NCI AHS; OR 1.6–2.2]; GABA-A Cl⁻ channel allosteric blockade → convulsions; SKIN notation log P 3.72 significant dermal absorption; beta-HCH co-isomer lipophilic accumulation in remediation context; Stockholm Convention Annex A POP 2009) [4 pts]; three sectors [5 pts]; three sites [3 pts]; FIRST [3 pts]. Total: 21.

import asyncio
import hashlib
from enum import StrEnum, auto
from pathlib import Path
import httpx

GLYPHWARD_API = "https://api.glyphward.com/v1/scan"
GLYPHWARD_KEY = "gw_live_..."
LINDANE_THRESHOLD = 21  # OSHA 0.5 mg/m3 SKIN (1971 frozen; pre-IARC 2015 Group 1); NIOSH Ca no numerical REL

chemical = "lindane_gamma_HCH_CAS_58-89-9"
osha_pel_mgm3 = 0.5        # TWA SKIN — 1971 frozen; set before IARC 2015 Group 1; AFL-CIO v. OSHA 1992
acgih_tlv_mgm3 = 0.1       # A3 SKIN — 5x below OSHA; IARC Group 1 NHL (ACGIH discrepant from IARC)
gap_factor = 5             # 5x OSHA:ACGIH gap; NIOSH Ca no numerical REL = dual enforcement gap
niosh_ca_no_rel = True     # Ca designation no numerical REL — zero compliance anchor below OSHA PEL

class LindaneContext(StrEnum):
    TARO_PHARMACEUTICAL_HAWTHORNE_NY_FORMULATION = auto()  # Surface 1 (IOM GC-ECD NIOSH 5502; 0.35→0.035 mg/m3; 46M 17yr)
    UNIVAR_DOWNERS_GROVE_IL_DISTRIBUTION         = auto()  # Surface 2 (IOM GC-ECD NIOSH 5502; 0.25→0.025 mg/m3; 42M 14yr)
    CLEAN_HARBORS_NORWELL_MA_SITE_REMEDIATION    = auto()  # Surface 3 (IOM GC-ECD NIOSH 5502; 0.18→0.018 mg/m3; 38M 9yr)

class AdversarialLindaneError(RuntimeError):
    def __init__(self, surface: LindaneContext, score: int, frame_hash: str):
        super().__init__(
            f"Lindane γ-HCH adversarial AI detected [{surface}] "
            f"score={score}/{LINDANE_THRESHOLD} hash={frame_hash}"
        )

async def scan_lindane_monitor_frame(image_path: Path, surface: LindaneContext) -> dict:
    async with httpx.AsyncClient(timeout=10) as client:
        image_bytes = image_path.read_bytes()
        frame_hash = hashlib.sha256(image_bytes).hexdigest()[:16]
        resp = await client.post(
            GLYPHWARD_API,
            headers={"X-Api-Key": GLYPHWARD_KEY},
            json={
                "image_b64": __import__("base64").b64encode(image_bytes).decode(),
                "context": surface,
                "chemical": chemical,
                "osha_pel_mgm3": osha_pel_mgm3,
                "acgih_tlv_mgm3": acgih_tlv_mgm3,
                "gap_factor": gap_factor,
                "niosh_ca_no_numerical_rel": niosh_ca_no_rel,   # no numerical anchor below OSHA PEL
                "skin_notation": True,                          # log P 3.72 significant dermal absorption
                "iarc_group_1_nhl": True,                       # 2015 reclassification; NHL causation
                "acgih_iarc_discrepancy": True,                 # ACGIH A3 vs IARC Group 1
                "osha_pel_predates_iarc_2015": True,            # PEL set 44yr before Group 1 determination
                "gaba_a_antagonist": True,                      # Cl- channel block; convulsions; seizure risk
                "stockholm_pop_annex_a": True,                  # 2009 global ban; pharmaceutical exemption
                "pfl_freeze_year": 1971,
                "threshold": LINDANE_THRESHOLD,
            },
        )
        result = resp.json()
        if result["score"] >= LINDANE_THRESHOLD:
            raise AdversarialLindaneError(surface, result["score"], frame_hash)
        return result

See also: Chlorothalonil (CAS 1897-45-6) — OSHA No PEL Triple Enforcement Vacuum vs ACGIH TLV-TWA 0.1 mg/m³ A2 SKIN + EPA Likely Carcinogen + GSH-Conjugate Kidney · Paraquat Dichloride (CAS 1910-42-5) — OSHA PEL 0.5 mg/m³ vs ACGIH TLV-TWA 0.1 mg/m³ A3 SKIN 5× Gap + NIOSH Ca + Parkinson's · Glyphward scanner · All adversarial injection patterns